Eupraxia Pharmaceuticals Inc.
EPRXF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | 0.12 | -0.00 | 0.26 |
| FCF Yield | -21.07% | -27.17% | -36.40% | -0.88% |
| EV / EBITDA | -3.24 | -2.50 | -1.45 | -32.64 |
| Quality | ||||
| ROIC | -252.70% | -107.33% | -67.58% | 38.64% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.73 | 0.79 | 0.63 | 0.10 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -46.79% | -26.61% | -3,631.69% | 92.20% |
| Safety | ||||
| Net Debt / EBITDA | 0.31 | 0.63 | 0.55 | -7.05 |
| Interest Coverage | -23.99 | -14.25 | -16.10 | -1.19 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |